Physician profile
Jessica E Ramirez
NPI 1245973965
$1,130.46
in general payments reported to CMS, 2019-2025
12 companies · $172 in 2025
The $172 reported for 2025 was more than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $95.60 · 2023: $381 · 2024: $482 · 2025: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,035.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,034.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $356.52 | 2023-2024 | |
| Glaxosmithkline, LLC. | $182.55 | 2023-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $146.47 | 2025 | Breztri, Airsupra |
| E.R. Squibb & Sons, L.L.C. | $95.60 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $66.68 | 2024-2025 | |
| Novo Nordisk INC | $58.66 | 2023-2024 | |
| Lilly USA, LLC | $51.53 | 2024 | Mounjaro |
| Vifor Pharma, INC. | $51.40 | 2023-2024 | Veltassa |
| Amgen INC. | $46.74 | 2024 | Repatha, Otezla |
| Shield Therapeutics INC | $32.05 | 2023-2024 | Accrufer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.03 | 2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.23 | 2024 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.